Selective GIP Receptor Peptides for Metabolic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptidic compounds for treating diabetes and obesity have limited half-life, stability issues, and often cause gastrointestinal side effects like nausea and vomiting, necessitating the development of highly selective GIP receptor agonists with improved solubility, stability, and prolonged action.
Innovation Solution
Development of exendin-4 derived peptides with specific structural modifications, such as substitutions at positions 14, 17, and 26, that selectively activate the GIP receptor with high affinity while minimizing activity at the GLP-1 receptor, enhancing stability and solubility, and combining with GLP-1 receptor agonists for enhanced therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exendin-4 peptide analogues are used to activate GLP-1 receptor, then glucose lowering effect is improved, but GIP receptor selectivity deteriorates
Solution Approach 1:
The patent applies local quality by making specific modifications at particular positions (14, 17, 26) of the exendin-4 peptide sequence. These localized changes create distinct binding characteristics that favor GIP receptor activation while maintaining GLP-1 receptor activity, achieving selective agonism without requiring complete sequence redesign.
Solution Approach 2:
The patent utilizes parameter changes by modifying the peptide structure at specific positions to alter its receptor binding properties. The modifications at positions 14, 17, and 26 change the peptide's pharmacological parameters to achieve high GIP receptor selectivity while maintaining glucose lowering efficacy.
2Reliability
If peptidic compounds are used for diabetes treatment, then therapeutic efficacy is improved, but half-life is limited
Solution Approach 1:
The patent applies parameter changes by modifying the peptide sequence and incorporating modifications that resist enzymatic degradation. These changes alter the peptide's pharmacokinetic parameters to extend half-life while preserving therapeutic efficacy through maintained receptor binding and signaling activity.
3Reliability
If peptidic compounds are used for diabetes treatment, then glucose control is improved, but stability issues occur
Solution Approach 1:
The patent utilizes parameter changes by introducing structural modifications that enhance peptide stability against enzymatic degradation. These changes include modifications at positions 14, 17, and 26 that reduce susceptibility to proteolytic cleavage while maintaining glucose control efficacy through preserved receptor activation.
4Reliability
If GLP-1 receptor agonists are used, then glucose lowering is improved, but gastrointestinal side effects increase
Solution Approach 1:
The patent applies segmentation by separating the therapeutic effects from the harmful effects through selective receptor activation. By creating a peptide that preferentially activates GIP receptor over GLP-1 receptor, the invention isolates the beneficial glucose lowering effect from the harmful gastrointestinal side effects, reducing nausea and vomiting while maintaining glycemic control.
Solution Approach 2:
The patent utilizes parameter changes by modifying the peptide's receptor binding specificity to reduce gastrointestinal side effects. The structural modifications create a peptide with altered pharmacological parameters that activates GIP receptor preferentially, thereby reducing the incidence of GI adverse events while preserving glucose lowering activity.
Data Source
AI summary
The present invention relates to peptidic selective GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, hyperglycemia, as well as the treatment of disorders associated with nausea and vomiting.